Vesicular LL-37 contributes to inflammation of the lesional skin of palmoplantar pustulosis.
about
What do we know about palmoplantar pustulosis?[Pustular psoriasis].Efficacy and Safety of Guselkumab, an Anti-interleukin 23 Monoclonal Antibody, for Palmoplantar Pustulosis: A Randomized Clinical Trial.Phase III clinical study of maxacalcitol ointment in patients with palmoplantar pustulosis: A randomized, double-blind, placebo-controlled trial.
P2860
Vesicular LL-37 contributes to inflammation of the lesional skin of palmoplantar pustulosis.
description
2014 nî lūn-bûn
@nan
2014 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Vesicular LL-37 contributes to ...... in of palmoplantar pustulosis.
@ast
Vesicular LL-37 contributes to ...... in of palmoplantar pustulosis.
@en
Vesicular LL-37 contributes to ...... in of palmoplantar pustulosis.
@nl
type
label
Vesicular LL-37 contributes to ...... in of palmoplantar pustulosis.
@ast
Vesicular LL-37 contributes to ...... in of palmoplantar pustulosis.
@en
Vesicular LL-37 contributes to ...... in of palmoplantar pustulosis.
@nl
prefLabel
Vesicular LL-37 contributes to ...... in of palmoplantar pustulosis.
@ast
Vesicular LL-37 contributes to ...... in of palmoplantar pustulosis.
@en
Vesicular LL-37 contributes to ...... in of palmoplantar pustulosis.
@nl
P2093
P2860
P1433
P1476
Vesicular LL-37 contributes to ...... in of palmoplantar pustulosis.
@en
P2093
Hidenori Okazaki
Kenji Kameda
Koji Sayama
Masamoto Murakami
Mikiko Tohyama
Takaaki Kaneko
Teruaki Nakatsuji
Yasushi Hanakawa
P2860
P304
P356
10.1371/JOURNAL.PONE.0110677
P407
P577
2014-10-16T00:00:00Z